Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pizotifen malate, quantity: 0.725 mg - tablet, sugar coated - excipient ingredients: colloidal anhydrous silica; povidone; acacia; purified talc; sucrose; lactose monohydrate; cetyl palmitate; magnesium stearate; maize starch; titanium dioxide - indications as at 14 june 2004: prophylactic (interval) treatment of vascular headaches: typical and atypical migraine, vasomotor headache, cluster headache (horton's syndrome). sandomigran is without effect in the migraine attack. for this purpose preparations containing ergotamine are recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pizotifen malate 0.725mg equivalent to 0.5 mg pizotifen;  ;   - tablet - 500 mcg - active: pizotifen malate 0.725mg equivalent to 0.5 mg pizotifen     excipient: acacia cetyl palmitate colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone purified talc   sucrose titanium dioxide - indications prophylactic treatment of recurrent vascular headaches, such as · typical or atypical migraine · vasomotor headache · cluster headache (horton's syndrome). sandomigran is less effective in tension headache and in psychogenic and post-traumatic headaches. it is not effective in relieving migraine attacks once in progress.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - pizotifen maleate - coated tablets - 1.5 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - pizotifen 1mg - tablet - 1 mg - active: pizotifen 1mg

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - pizotifen maleate - coated tablets - 500 microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - pizotifen hydrogen malate - oral tablet - 1.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - pizotifen hydrogen malate - oral tablet - 1.5mg

Canada - English - Health Canada

paladin labs inc. - pizotifen (pizotifen malate) - tablet - 1mg - pizotifen (pizotifen malate) 1mg - antimigraine agents, miscellaneous

Namibia - English - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - pizotifen hydrogen maleate as pizotifen base 0.5mg - tablet - 0.5mg pizotifen /tablet

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - everolimus, quantity: 10 mg - tablet - excipient ingredients: butylated hydroxytoluene; hypromellose; lactose monohydrate; lactose; crospovidone; magnesium stearate - the treatment of: - postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole and anastrozole - progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin - advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib - subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection - patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.